Gyre Therapeutics, Inc. Selling and Marketing Expense
Gyre Therapeutics, Inc. (GYRE) reported Selling and Marketing Expense of $13.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-07
- Gyre Therapeutics, Inc. selling and marketing expense for the quarter ending 2026-06-30 was $13.75M, a 9.48% decline year-over-year.
- Gyre Therapeutics, Inc. selling and marketing expense for the quarter ending 2026-03-31 was $14.14M, a 30.39% increase year-over-year.
- Gyre Therapeutics, Inc. selling and marketing expense for the quarter ending 2025-12-31 was $23.82M, a 41.29% increase year-over-year.
- Gyre Therapeutics, Inc. selling and marketing expense for the quarter ending 2025-09-30 was $15.33M, a 11.89% increase year-over-year.
- Gyre Therapeutics, Inc. selling and marketing expense for fiscal 2025 was $65.18M, a 13.33% increase from fiscal 2024.
- Gyre Therapeutics, Inc. selling and marketing expense for fiscal 2024 was $57.51M, a 5.96% decline from fiscal 2023.
- Gyre Therapeutics, Inc. selling and marketing expense for fiscal 2023 was $61.16M, a 12.76% increase from fiscal 2022.
- Gyre Therapeutics, Inc. selling and marketing expense for fiscal 2022 was $54.24M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $13.75M 10-Q · filed 2026-08-07 | $27.89M 10-Q · filed 2026-08-07 | $51.71M derived: sum of 3 quarters · filed 2026-08-07 | $67.03M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $14.14M 10-Q · filed 2026-05-08 | $37.95M derived: sum of 2 quarters · filed 2026-05-08 | $53.28M derived: sum of 3 quarters · filed 2026-05-08 | $68.47M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $23.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $39.14M derived: sum of 2 quarters · filed 2026-03-13 | $54.34M derived: sum of 3 quarters · filed 2026-08-07 | $65.18M 10-K · filed 2026-03-13 | |
| 2025-09-30 | $15.33M 10-Q · filed 2025-11-07 | $30.52M derived: sum of 2 quarters · filed 2026-08-07 | $41.36M 10-Q · filed 2025-11-07 | $58.22M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $15.20M 10-Q · filed 2026-08-07 | $15.19M 10-Q · filed 2025-08-11 | $26.04M 10-Q · filed 2026-08-07 | $42.89M derived: sum of 3 quarters · filed 2026-08-07 | $56.59M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $10.84M 10-Q · filed 2026-05-08 | $27.70M derived: sum of 2 quarters · filed 2026-05-08 | $41.40M derived: sum of 3 quarters · filed 2026-05-08 | $55.81M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $16.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $30.55M derived: sum of 2 quarters · filed 2026-03-13 | $44.97M derived: sum of 3 quarters · filed 2026-03-13 | $57.51M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $13.70M 10-Q · filed 2025-11-07 | $28.11M derived: sum of 2 quarters · filed 2025-11-07 | $40.66M 10-Q · filed 2025-11-07 | $57.12M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $14.41M 10-Q · filed 2025-08-11 | $26.96M 10-Q · filed 2025-08-11 | $43.42M derived: sum of 3 quarters · filed 2025-08-11 | $57.35M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $12.54M 10-Q · filed 2025-05-09 | $29.01M derived: sum of 2 quarters · filed 2025-05-09 | $42.93M derived: sum of 3 quarters · filed 2025-05-09 | $60.93M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $16.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $30.39M derived: sum of 2 quarters · filed 2025-03-17 | $48.39M derived: sum of 3 quarters · filed 2025-03-17 | $61.16M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $13.93M 10-Q · filed 2024-11-13 | $31.93M derived: sum of 2 quarters · filed 2024-11-13 | $44.70M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $18.00M 10-Q · filed 2024-08-13 | $30.77M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $12.77M 10-Q · filed 2024-05-13 | ||||
| 2022-12-31 | $54.24M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |